Valuation: China Isotope & Radiation Corporation

Market Cap 4.85B 5.6B 714M 627M 577M 537M 1.01B 67.85B 1.03B 6.94B 2.69B 33.3B 2.68B 2.62B 116B P/E 2024
8.03x
P/E 2025 17.7x
Enterprise Value 4.97B 5.73B 731M 642M 591M 551M 1.04B 69.51B 1.06B 7.11B 2.75B 34.12B 2.75B 2.69B 119B EV / Sales 2024
0.42x
EV / Sales 2025 0.82x
Free-Float
91.21%
Yield 2024
3.74%
Yield 2025 1.69%
06-18 China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended 31 December 2025, Payable on Before 17 August 2026 CI
06-18 China Isotope & Radiation Corporation Appoints Zhang Guoliang as A Member of Legal Affairs Committee of the Board and A Member of Science and Technology Innovation Committee of the Board CI
05-26 China Isotope Proposes Auditor Change MT
05-26 China Isotope & Radiation Corporation Announces Ma Xiaoyu Resignation of Ma Xiaoyu as an Executive Director Member of the Legal Affairs Committee Science and Technology Innovation Committee, Effective May 26, 2026 CI
03-27 China Isotope & Radiation final cash dividend of RMB0.2264 per share RE
03-27 China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended December 31, 2025, Payable Before 17 August 2026 CI
03-27 China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-19 China Isotope & Radiation to buy 51% stake in Hunan Huifeng Engineering Detection RE
03-13 China Isotope & Radiation Corporation, Zhonghe Headway and the People?s Government of Maoming Municipality Enter Strategic Cooperation Agreement CI
03-13 China Isotope & Radiation says co and Zhonghe Headway enter strategic cooperation agreement with Maoming municipality RE
03-02 China Isotope & Radiation's Unit Gets China Nod for Market Launch of Breath Analyzer MT
02-12 China Isotope & Radiation Warns of Up to 25% Lower 2025 Profit MT
02-12 China Isotope & Radiation Corporation Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025 CI
1 day+0.74%
1 week-0.51%
Current month+0.74%
1 month-5.77%
3 months-11.85%
6 months-17.62%
Current year-12.72%
1 week 17.02
Extreme 17.02
18.7
1 month 17.02
Extreme 17.02
20.22
Current year 17.02
Extreme 17.02
24.28
1 year 14.28
Extreme 14.28
25
3 years 9.03
Extreme 9.03
25
5 years 9.03
Extreme 9.03
32.1
10 years 9.03
Extreme 9.03
35.4
Manager TitleAgeSince
Chief Executive Officer 55 2024-08-01
Corporate Secretary - 2024-08-29
Corporate Secretary - 2024-08-29
Director TitleAgeSince
Director/Board Member 57 2017-02-21
Director/Board Member 54 2019-06-27
Director/Board Member 54 2019-12-29
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%-0.51%+15.99%+14.48% 714M
+13.82%+24.69%+236.76%+377.01% 22.64B
+0.21%+0.21%-40.67%-24.93% 9.42B
-1.78%+3.92%+37.19%+29.84% 7.09B
+5.22%+3.31%-29.27% - 5.3B
+1.85%+12.86%+223.80%-30.07% 4.96B
+4.31%+5.06%-22.39%-25.75% 5.07B
-1.64%+2.16%+89.84%+97.44% 4.28B
+0.26%+5.42%-23.33%-25.21% 4.21B
+3.03%+0.13%-20.14%-42.20% 2.51B
Average +2.61%+5.05%+46.78%+41.18% 6.62B
Weighted average by Cap. +5.49%+10.84%+95.62%+138.75%

Financials

2024 2025
Net sales 7.57B 8.74B 1.11B 979M 901M 840M 1.58B 106B 1.62B 10.84B 4.2B 52.03B 4.19B 4.1B 181B 7.19B 8.3B 1.06B 929M 855M 797M 1.5B 101B 1.53B 10.28B 3.98B 49.37B 3.97B 3.89B 172B
Net income 407M 469M 59.85M 52.55M 48.37M 45.07M 85M 5.69B 86.73M 582M 225M 2.79B 225M 220M 9.72B 327M 378M 48.19M 42.31M 38.95M 36.29M 68.44M 4.58B 69.83M 468M 181M 2.25B 181M 177M 7.83B
Net Debt -109M -126M -16.03M -14.08M -12.96M -12.07M -22.77M -1.52B -23.23M -156M -60.38M -748M -60.2M -58.9M -2.6B 119M 137M 17.49M 15.36M 14.14M 13.17M 24.84M 1.66B 25.35M 170M 65.87M 816M 65.67M 64.25M 2.84B
Logo China Isotope & Radiation Corporation
China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.
Employees
3,578
Date Price Change Volume
26-07-02 HK$17.63 +0.74% 22,400
26-06-30 HK$17.50 +0.40% 18,400
26-06-29 HK$17.43 +0.75% 91,000
26-06-26 HK$17.30 -2.37% 66,600
26-06-25 HK$17.72 +0.28% 190,800

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1763 Stock